|
|
|
|
|
PEER-TO-PEER CLINICAL CONVERSATIONS |
|
|
|
|
|
| Increased Risk for CV Disease in Men with Prostate Cancer
|
| Alicia Morgans, MD, MPH
|
| Oliver Sartor and Alicia Morgans discuss the possibility of mitigating CV risk by appropriate selection of therapy and counseling patients related to their cardiovascular risk. They highlight the study findings from the prospective phase 3 HERO trial in which cardiovascular events were identified as a key adverse event with lower rates of major adverse cardiovascular events in patients treated with relugolix, the GnRH antagonist, as compared to patients treated with leuprolide, a GnRH agonist.
|
|
|
|
|
|
|
|
|
|
|
|
| The Cardiovascular Complications of Therapy for Patients with Prostate Cancer |
| Vivek K. Narayan, MD, MS |
| Joining Alicia Morgans, MD, MPH, is Vivek Narayan, MD, MS to highlight a paper on Cardiovascular Toxicities of Therapy for Genitourinary Malignancies and how these toxicities really relate to prostate cancer treatment. Dr. Narayan emphasizes the key to managing CV toxicities is awareness. |
|
|
|
|
|
|
|
|
|
|
|
| Cardiovascular Disease and Androgen Axis - Targeted Drugs for Prostate Cancer |
| Javid Moslehi, MD |
| Javid Moslehi joins Alicia Morgans to discuss the cardiovascular risks, as they relate to ADT in men with prostate cancer, from a cardio-oncologist perspective. |
|
|
|
|
|
|
|
|
|
|
|
| Real-World Analyses of Major Adverse Cardiovascular Event Risk by Drug Class After Initiation of ADT
|
| E. David Crawford, MD
|
| E. David Crawford presents the results of a real-world analyses of major adverse cardiovascular event (MACE) risk by drug class after initiation of ADT. This study aims to evaluate MACE risk after ADT initiation with LHRH agonists versus LHRH antagonists using real-world data. However, in the current analysis, MACE risk was lower in patients treated with LHRH agonists versus antagonists in the first seven years after ADT initiation.
|
|
|
|
|
|
| Major Adverse Cardiovascular Event Risk After ADT Initiation Is Higher For Older Patients
|
| E. David Crawford, MD
|
| Patients with prostate cancer (PCa) treated with androgen deprivation therapy (ADT) may experience major adverse cardiovascular events (MACE). There is some debate as to how much of MACE is caused by ADT itself. Some risk factors that might influence MACE are increasing age and higher BMI. A study in the general population found that the rate of cardiovascular (CV) disease was approximately 15% higher for individuals 80 years and older compared to those 60 to 79 years old. This study evaluated MACE risk for PCa patients in different age and BMI groups using real-world data.
|
|
|
|
|
|
|
|
|
|
|
| Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer: Pooled Safety Analyses from Randomized Controlled Studies
|
| Neal D. Shore, MD, FACS
|
| Neal Shore discusses oral relugolix for ADT in advanced prostate cancer, specifically a pooled safety analysis from randomized trials. Relugolix is an FDA approved, first-in-class oral, highly selective gonadotropin-releasing hormone antagonist that is given once daily. In the pooled analyses of 2 randomized clinical studies in advanced prostate cancer, relugolix was generally well tolerated, with a lesser incidence of major adverse cardiovascular events relative to leuprolide.
|
|
|
|
|
|
| Risk of Metabolic and Cardiovascular Adverse Events with Abiraterone or Enzalutamide Among Men with Advanced Prostate Cancer |
| Lillian Lai, MD, MS |
| In a moderated poster presentation at the 2022 American Urologic Association Annual Meeting, Lillian Lai discussed the risk of metabolic and cardiovascular toxicity in men receiving abiraterone or enzalutamide for advanced prostate cancer. Each of these treatments, along with ongoing androgen deprivation therapy (ADT), are guidelines indicated for the management of men with advanced prostate cancer. |
|
|
|
|
|
| Cardiovascular Causes of Death in Patients Treated for Localized Prostate Cancer |
| Abdenour Nabid, MD |
| Abdenour Nabid discusses the cardiovascular causes of death in patients treated for localized prostate cancer. From two trials in localized prostate cancer, cardiovascular disease represented the second cause of death. Based on Dr. Nabid and colleagues’ data, they retrieved and reviewed the clinical information on those patients labelled by investigators as dying from cardiovascular disease aiming to confirm and precisely define the cause/diagnosis of their cardiovascular death. |
|
|
|
|
|
| Abdominal Aorto-Iliac Calcification Burden Assessment Using Deep Convolutional Neural Networks for Prediction of Cardiovascular Risk Among Prostate Cancer Patients Undergoing Stereotactic Body Radiotherapy |
| William C. Chen, MD |
| William Chen discusses the abdominal aorto-iliac calcification burden assessment using deep convolutional neural networks for prediction of cardiovascular risk among patients undergoing stereotactic body radiotherapy. Cardiovascular disease is among the leading causes of death for patients with prostate cancer. |
|
|
|
|
|
 |
